# First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

> **NCT03401385** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 890 (estimated)

## Conditions studied

- Hormone Receptor Positive Breast Cancer
- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Datopotamab Deruxtecan (Dato-DXd)
- **DRUG:** Steroid Containing Mouthwash
- **OTHER:** Non-Steroid Containing Mouthwash

## Key facts

- **NCT ID:** NCT03401385
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-31
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 890 (ESTIMATED)
- **Last updated:** 2025-10-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03401385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03401385, "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03401385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*